{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:16:36Z","timestamp":1792815396835,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Oral SERDs are under extensive development to overcome fulvestrant main limitations, including intramuscular-only formulation and poor performance in early-stage hormone receptor-positive (HR+)\/HER2-negative breast cancer. This review summarizes the most relevant evidence published so far and envisions the potential integration of oral SERDs in the therapeutic algorithm of HR+\/HER2-negative metastatic breast cancer (MBC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Amcenestrant and giredestrant, two of the most promising oral SERDs, recently failed to show a significant improvement in progression-free survival (PFS) in pivotal trials. Conversely, elacestrant demonstrated significant PFS superiority over standard-of-care endocrine therapy (aromatase inhibitors or fulvestrant) in MBC. Additionally, it did not show unusual side effects observed with other oral SERDs, like bradycardia, hematotoxicity and vision impairment, and proved to be effective also in case of <jats:italic toggle=\"yes\">ESR1<\/jats:italic>-mutant endocrine-resistant breast cancer. Combination trials of oral SERDs with target agents, such as CDK4\/6-inhibitors, are ongoing. Finally, some window-of-opportunity trials showed promising on-target activity in early-stage for this drug class.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Promising results from early-phase trials are not translating into sufficient clinical benefit in pivotal trials of main oral SERDs in monotherapy, except for elacestrant. Whether oral SERDs might become the backbone for combination strategies in MBC or the preferred (neo)adjuvant endocrine agents is under evaluation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000892","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T09:00:14Z","timestamp":1661331614000},"page":"635-642","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment"],"prefix":"10.1097","volume":"34","author":[{"given":"Isabel","family":"Garcia-Fructuoso","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gomez-Bravo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Schettini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona"},{"name":"Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)"},{"name":"Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/cancers13061458","article-title":"Endocrine-based treatments in clinically-relevant subgroups of hormone receptor-positive\/HER2-negative metastatic breast cancer: systematic review and meta-analysis","volume":"13","author":"Schettini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2016.03.012","article-title":"Hormone receptor\/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going","volume":"46","author":"Schettini","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.3390\/ijms22157812","article-title":"Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective","volume":"22","author":"Hernando","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-019-05296-8","article-title":"Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+\/HER2-) early breast cancer (EBC): results from the GEICAM\/2006-10 study","volume":"177","author":"Ru\u00edz-Borrego","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1186\/bcr3393","article-title":"A randomized trial to assess the biological activity of short-term (presurgical) fulvestrant 500\u200amg plus anastrozole versus fulvestrant 500\u200amg alone or anastrozole alone on primary breast cancer","volume":"15","author":"Robertson","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"(15 suppl)","key":"R10-20250526","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2020.38.15_suppl.504","article-title":"ALTERNATE: neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: alliance A011106","volume":"38","author":"Ma","year":"2020","journal-title":"JCO"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/1078-0432.CCR-21-1095","article-title":"A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Jhaveri","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-17-3102","article-title":"A first-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER+\/HER2- advanced breast cancer","volume":"24","author":"Hamilton","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"(15 suppl)","key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2021.39.15_suppl.1063","article-title":"Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+\/HER2\u2013 advanced breast cancer: phase 1 results","volume":"39","author":"Maglakelidze","year":"2021","journal-title":"JCO"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/13543784.2021.1983542","article-title":"Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer","volume":"31","author":"Chen","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1200\/JCO.20.02272","article-title":"Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer","volume":"39","author":"Bardia","year":"2021","journal-title":"J Clin Oncol"},{"key":"R17-20250526","first-page":"JCO2200338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD Trial","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1530\/ERC-15-0287","article-title":"Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader","volume":"22","author":"Wardell","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"(15 suppl)","key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.2021.39.15_suppl.1058","article-title":"AMEERA-1: Phase 1\/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+\/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)","volume":"39","author":"Chandarlapaty","year":"2021","journal-title":"JCO"},{"issue":"(15 Suppl)","key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2020.38.15_suppl.1023","article-title":"A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer","volume":"38","author":"Lim","year":"2020","journal-title":"JCO 20 de mayo de"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"S1285","DOI":"10.1016\/j.annonc.2021.08.2086","article-title":"LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+\/HER2\u2013 eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study","volume":"32","author":"Hurvitz","year":"2021","journal-title":"Ann Oncol"},{"issue":"(16 suppl)","key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2022.40.16_suppl.1021","article-title":"A phase 1a\/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): monotherapy results from EMBER","volume":"40","author":"Jhaveri","year":"2022","journal-title":"JCO"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:05:40Z","timestamp":1748300740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000892","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}